Skip to content
AiSeekAiSeek
Sign in
NewMarketsReported 2026-10-07 18:00

Boston Scientific appoints Joseph M. Fitzgerald as Executive Vice President and Chief Operating Officer

Boston Scientific announced the appointment of Joseph M. Fitzgerald as Executive Vice President and Chief Operating Officer, effective January 1, 2027. The company will also establish three new reportable segments—Interventional Therapies, Rhythm Solutions, and MedSurg—effective the same date to support faster decision-making and strategic investment allocation.

Why it matters. The leadership change and organizational restructuring affect Boston Scientific's global operations and strategic direction, potentially influencing its operational efficiency and growth execution across medical technology markets.

01

Who it touches

  1. 1Boston Scientific
  2. operates in →Fact
    2Medical technologyIndustry
  3. produces →Fact
    3BPH treatmentsProduct
  4. acquires →Fact
    4PenumbraCompany
  5. operates in →Fact
    5urology device marketMarket
02

Evidence

  • PPR Newswire news releasesCompany2026-10-07 18:00
    Rhythm Solutions will include Electrophysiology, WATCHMAN and Cardiac Rhythm Management & Diagnostics
    View source
  • PPR Newswire news releasesCompany2026-10-07 18:00
    Fitzgerald currently serves as executive vice president and group president, Cardiovascular, Boston Scientific.
    View source
  • PPR Newswire news releasesCompany2026-10-07 18:00
    Boston Scientific Corporation (NYSE: BSX) today announced the appointment of Joseph M. Fitzgerald to executive vice president and chief operating officer (COO), effective Jan. 1, 2027.
    View source
  • PPR Newswire news releasesCompany2026-10-07 18:00
    As a global medical technology leader for more than 45 years
    View source
  • PPR Newswire news releasesCompany2026-10-07 18:00
    MedSurg will include Endoscopy, Urology and Neuromodulation.
    View source
  • PPR Newswire news releasesCompany2026-10-07 18:00
    Interventional Therapies will include the Interventional Cardiology, Vascular Therapies and Interventional Oncology & Embolization businesses
    View source
  • PPR Newswire news releasesCompany2026-10-07 18:00
    In connection with Fitzgerald's appointment, Boston Scientific will establish three reportable segments* — Interventional Therapies, Rhythm Solutions and MedSurg also effective Jan. 1. As the company continues to grow and expand its portfolio, the structure is designed to enable…
    View source
  • PPR Newswire news releasesCompany2026-10-07 18:00
    MARLBOROUGH, Mass., Oct. 7, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the appointment of Joseph M. Fitzgerald to executive vice president and chief operating officer (COO), effective Jan. 1, 2027.
    View source
  • MMedTech DiveMedia2026-10-08 18:55
    View source